Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;46(5):2055-2071.
doi: 10.1007/s10072-025-07987-1. Epub 2025 Jan 14.

Use of vortioxetine in different neurological fields: a systematic review and future perspectives

Giulio Verrienti  1 , Isabella Colonna  2 , Cecilia Raccagni  3
Affiliations

Use of vortioxetine in different neurological fields: a systematic review and future perspectives

Giulio Verrienti et al. Neurol Sci. 2025 May.

Abstract

Introduction: Vortioxetine is a multimodal antidepressant with a high tolerability profile. Recent evidence suggests a role for vortioxetine in improving cognitive function and reducing functional disability linked to depression. We conducted a systematic review on the use of vortioxetine in different neurological disorders.

Methods: PubMed was searched for articles published from inception until June 2024. Article reference lists were screened, and relevant articles were retrieved for consultation. Clinical trials focused on the use of vortioxetine in cerebrovascular diseases, movement disorders and cognitive impairments were included. The systematic review protocol was developed using guidance from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

Results: Our search identified 236 citations, 8 of which ultimately met the criteria for inclusion in the synthesis. The included studies consisted of 3 randomized controlled trials, 1 nonrandomized clinical trial and 4 single-arm observational studies. Subsequently, we grouped these articles into three sections of neurological interest (cerebrovascular diseases, movement disorders and cognitive dysfunction).

Conclusions: Through its multimodal mechanism of action, the antidepressant vortioxetine shows potential benefit in improving depressive symptoms in patients with depression and different, comorbid neurological condition. In addition, the pro-cognitive effect of this agent may represent a possible indication for its use in the treatment of adults with depression and/or neurological cognitive impairment. Future research is needed to explore and clarify other possible implications for a rational administration of this molecule in other neurological fields.

Keywords: Cognitive effects; Dementia; Multimodal antidepressant; Stroke; Vortioxetine.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: Not applicable. Conflict of interest: Giulio Verrienti, Isabella Colonna and Cecilia Raccagni declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

References

    1. Adair M, Christensen MC, Florea I, Loft H, Fagiolini A (2023) Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: an updated analysis of efficacy and tolerability. J Affect Disord 328:345–354. https://doi.org/10.1016/j.jad.2023.01.074 Epub 2023 Jan 26. PMID: 36708956 - DOI - PubMed
    1. Li Z, Liu S, Wu Q, Li J, Yang Q, Wang X, Peng P, Wang Q, Liu Y, Li M, Hao Y, Xu H, He L, Wang Y, Chen S, Liu T (2023) Effectiveness and safety of Vortioxetine for the treatment of major depressive disorder in the Real World: a systematic review and Meta-analysis. Int J Neuropsychopharmacol 26(6):373–384. https://doi.org/10.1093/ijnp/pyad018 PMID: 37105713; PMCID: PMC10289145 - DOI - PubMed - PMC
    1. Zhang X, Cai Y, Hu X, Lu CY, Nie X, Shi L (2022) Systematic review and Meta-analysis of Vortioxetine for the treatment of major depressive disorder in adults. Front Psychiatry 13:922648. https://doi.org/10.3389/fpsyt.2022.922648 PMID: 35815048; PMCID: PMC9263295 - DOI - PubMed - PMC
    1. Stahl SM (2015) Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr.;20(2):93– 7. https://doi.org/10.1017/S1092852915000139 . PMID: 25831967
    1. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl TB (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 54(9):3206–3221. https://doi.org/10.1021/jm101459g Epub 2011 Apr 12. PMID: 21486038 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources